MétaCan
Menu
Back to cohort
Record W2607528826

Preclinical assessment of a fixed dose combination of novel liposome formulations of idarubicin and gemcitabine showing improved antitumor activity

2005· article· en· W2607528826 on OpenAlexaff
Nancy Dos Santos, Alexander Van Hecke, Dana Masin, Marcel B. Bally

Bibliographic record

VenueCancer Research · 2005
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsGemcitabinePharmacologyDrugIdarubicinMedicineLiposomeTherapeutic indexPharmacokineticsChemotherapyCytarabineChemistryInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

1406 Objective: Combination chemotherapy regimens are the mainstay of cancer treatment. In general, established protocols utilizing drug combinations are empirically defined in late phase clinical trials. There is a need to identify effective drug combinations during preclinical studies. The purpose of the studies described herein was to achieve improved therapeutic activity by combining idarubicin (IDA) and gemcitabine (GEM). These drugs were chosen based on their complementary antitumor effects, non-overlapping toxicities and proven efficacy. It is further proposed that the therapeutic properties of the individual drugs will be enhanced when administered in appropriately selected liposomal formulations. The studies established a method to define a fixed dose combination product administered in preclinical animal models at doses selected on the basis of the toxic and therapeutic effects of the individual drugs, whether given alone or in a liposomal formulation. Methods: Combination drug treatments were prepared at drug/drug ratios defined on the basis of maximum tolerable dose (MTD) studies. The efficacy of the combination drug product comprised of free and/or liposomal drugs was then determined at three effective doses in a murine leukemia model. Results: In vitro cytotoxicity data, where combination effects were determined for several different drug/drug ratios, indicated that GEM and IDA exhibited moderate to strong synergism over a broad range of effective doses. A GEM lipid formulation was established in DSPC / Cholesterol / DSPE-PEG2000 (50:45:5 mole ratio). This lipid formulation significantly increased plasma drug circulation lifetimes (T1/2 = 14.3 h) when compared to free GEM (T1/2 = 2.1 h). Similarly, encapsulation of idarubicin in DSPC / DSPE-PEG2000 (98:2 mole ratio) significantly increased plasma drug circulation lifetimes (T1/2 = 6.7) when compared to free IDA (T1/2 = 1.2 h). The combination treatment of liposomal IDA (2 mg/kg) and liposomal GEM (3.4 mg/kg), evaluated in a murine leukemia model, resulted in a 281 % increase in life span (% ILS), yielding a synergistic effect as judged when compared to liposomal IDA (2 mg/kg; 156 % ILS) and liposomal GEM (5 mg/kg; 100 % ILS) administered as single agents. Interestingly, when IDA (2 mg/kg) and GEM (334 mg/kg) were administered as a combination of free drugs, a much lower (125 %) ILS was observed. Conclusions: The combination of IDA and GEM in vitro demonstrated synergistic cytotoxic activity over a broad range of concentrations. In a murine leukemia model, appropriate drug/drug ratios were chosen based on the MTD of a single dose administration for each drug. The combination of the liposomal drugs yielded synergistic % ILS, which was not observed for free/free or free/liposomal drug combinations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.204
GPT teacher head0.540
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer Treatment and PharmacologyFrench-language works237,207